Filing identity and reporting period
Important mismatch: The request metadata identifies Lisata Therapeutics, Inc. and 2019 Q2, but the supplied filing is Caladrius Biosciences, Inc.’s Form 10-Q for the quarter ended June 30, 2020, filed August 13, 2020. This summary covers the supplied filing, not the company and period in the metadata.
Caladrius is a clinical-stage biopharmaceutical company developing CD34+ cell therapies. It reported no product revenue in the supplied financial statements; operations are funded through cash, securities, equity financing, and research funding.
Financial performance and position
Amounts below are in millions of dollars, except per-share data. The filing presents expenses and cash-flow information, but no revenue or gross-margin measure.
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Research and development expense | $1.8 | $3.0 | $3.3 | $5.0 |
| General and administrative expense | $2.5 | $2.4 | $5.0 | $4.9 |
| Total operating expenses | $4.3 | $5.3 | $8.3 | $9.9 |
| Operating loss | $(4.3) | $(5.3) | $(8.3) | $(9.9) |
| Net income (loss) | $6.6 | $(5.1) | $2.6 | $(9.5) |
| Net income (loss) per share | $0.50 | $(0.49) | $0.22 | $(0.93) |
2020 net income includes a $10.9 million income tax benefit from selling New Jersey net operating losses (NOLs); absent this unusual item, the company remained loss-making at the operating level. Operating expenses declined year over year, mainly because R&D expense fell, partly offset by higher G&A expense.
At June 30, 2020, cash and cash equivalents were $26.7 million and marketable securities were $8.2 million, for combined liquidity of $34.9 million; working capital was $33.1 million. Total assets were $37.5 million, total liabilities $3.9 million, and total stockholders’ equity $33.6 million. The filing reports no borrowings; long-term liabilities primarily include operating lease liabilities. Cash increased by $12.7 million from year-end 2019.
For the six months, the cash-flow statement reports $0.3 million provided by operating activities, $2.9 million provided by investing activities, and $9.5 million provided by financing activities. Financing included net proceeds from April and May stock-and-warrant offerings and the at-the-market share sale. Cash-flow disclosure discrepancy: MD&A prose describes operating cash as used, while the cash-flow statement reports it as provided; investors should confirm the intended sign.
Material changes, outlook, and risks
- Financing and dilution: April and May 2020 offerings generated approximately $9.3 million gross proceeds combined and included warrants. The company also raised $1.3 million net under its HCW sales agreement during the first half. After quarter-end, it raised $2.0 million gross in a private placement and $6.9 million net through additional HCW share sales. Common shares outstanding were 15.6 million at June 30 and 19.3 million as of August 13, 2020. Further equity financing may dilute existing holders.
- Runway and funding dependence: Management believed cash on hand would fund operating expenses for at least 12 months after issuance of the financial statements, assuming the CLBS14 Phase 3 trial would not begin without additional dedicated capital. Management cautioned that financing may not be available on acceptable terms, or at all.
- Pipeline plans: FDA authorized an IND for CLBS119, a proposed study of CD34+ cell therapy for persistent lung damage following severe COVID-19; enrollment was expected to begin in the second half of 2020. CLBS12 enrollment in Japan had been slowed by the pandemic, with completion targeted by year-end 2020. Management expected to begin a CLBS16 Phase 2b trial by year-end 2020. CLBS14’s confirmatory Phase 3 trial remained on hold pending sufficient funding; the company estimated approximately $70 million in external costs over several years.
- COVID-19 and execution risks: The pandemic could disrupt trial enrollment, clinical sites, suppliers, travel, partnerships, and access to capital. The filing says the extent and duration of related impacts could not be reasonably estimated. Other key risks include clinical and regulatory uncertainty, the need for additional capital, and potential delays in development.
- Other items: The company sold $11.5 million of New Jersey NOLs for $10.9 million net proceeds, recorded as an income tax benefit. It disclosed no material change in legal proceedings, no material uncertain tax positions, and no off-balance-sheet arrangements. Disclosure controls were assessed as effective.
Most important facts for investors to verify
- Confirm the intended company and period: the source is Caladrius Biosciences’ Q2 2020 10-Q, not Lisata Therapeutics’ 2019 Q2 filing.
- Assess the effect of the one-time $10.9 million NOL-sale tax benefit when evaluating reported net income and ongoing operating losses.
- Reconcile the operating cash-flow sign conflict between the cash-flow statement and MD&A narrative.
- Track cash runway and subsequent financing alongside share-count growth, warrant overhang, and the conditions for starting the CLBS14 Phase 3 trial.
- Verify actual progress against the stated clinical-trial timelines and evaluate the continuing effects of COVID-19 on enrollment and operations.